The association between intravitreal ranibizumab therapy and serum cytokine concentrations in patients with diabetic macular edema
Sivashanth Gnanasekaran, Esther Bandala-Sanchez, Maria Kolic, Leonid Churilov, Sophie L Rogers, Annie K McAuley, Sukhpal S Sandhu, Salmaan Qureshi, Lyndell L Lim, Sanjeewa S Wickremasinghe
Molecular Vision | MOLECULAR VISION | Published : 2020
Aim: To investigate the association between intravitreal ranibizumab therapy and serum cytokine concentrations in patients with diabetic macular edema (DME). Methods: Twenty-five patients with center-involved DME were recruited prospectively. Serum samples were collected from the patients before and 4 weeks after two ranibizumab injections. The levels of 32 cytokines at these two time points were assessed using a multiplex array assay. Results: Following two ranibizumab injections, there was a statistically significant decrease in the median [interquartile range] levels of Interleukin 1-1beta (IL-1β) from 5.56 [3.6, 8.75] to 2.33 [1.51, 2.89], Interleukin 13 (IL-13) from 4.30 [1.84, 18.55] t..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) Early Career Fellowships
Funding sources: This study was supported by a grant from Novartis Pharma AG. SW (GNT 1128343) and LLL (GNT 1109330) are supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowships. The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government.